PR Newswire via NewsMotion·

Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity

Eli Lilly will showcase new data on retatrutide, Taltz, and Zepbound at ACR Convergence 2026, highlighting advancements in treating rheumatologic conditions and obesity.

Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity
Image accompanying the PR Newswire report.

Eli Lilly will present new research on retatrutide, Taltz, and Zepbound at ACR Convergence 2026, focusing on knee osteoarthritis and psoriatic arthritis with obesity.

Retatrutide trials showed substantial reductions in knee pain and weight in adults with knee osteoarthritis and obesity, with some experiencing no knee pain.

Taltz and Zepbound data demonstrated positive results in adults with psoriatic arthritis and obesity, with improvements in disease activity and metabolic outcomes.

Wire Provenance & Verification

Editorial brief compiled from certified PR Newswire wire reporting via Newsmotion News Desk.

Original Report →

Related Wire Dispatches · Essential Briefings

All News Wire (5+) →

Corporate Dispatches

Official company announcements, earnings disclosures, and corporate releases.

View Latest Wire →

Topic Dossiers

Special reports on conflict munitions, environmental monitoring, and civic journalism.

Browse Special Reports →

Issuer Newsroom

Distribute official press releases across the Newsmotion continental network.

Distribution Rates →